The Evolution Summit, taking place May 7-8, 2026 at The Ritz-Carlton, Fort Lauderdale, Florida. Designed as an ...

Interim results from RAINIER reveal that an 80 mg dose of povetacicept every four weeks delivered a 52% reduction in protein ...

Around half a million women in England will soon be able to access a non-hormonal treatment for hot flushes associated with menopause, after Astellas' Veoza was cleared for NHS use. Final draft ...

Steve Sanghera is the CEO and co-founder of Inventus. With over 20 years of experience in technology and telecommunications, ...

Genmab's recently approved therapy for cervical cancer that has come back or spread, Tivdak, has been turned down for NHS use in initial guidance from reimbursement authority NICE. Tivdak (tisotumab ...

Genetic diseases are notoriously challenging to treat, especially when each condition requires a tailored approach. With over 10,000 known genetic disorders, developing individual therapies for each ...

In a shock move, the co-founders of German mRNA specialist BioNTech – husband and wife team Uğur Şahin and Özlem Türeci – have said they are leaving to set up a new company. They are due to leave by ...

Siloed data is one of the most significant, yet overlooked, barriers to healthcare growth today; limiting doctors’ capacity to care for patients, diminishing hospital efficiency, and capping the speed ...

Ipsen said it will now pull Tazverik from the market in all countries where it has rights to the first-in-class, chemotherapy ...

In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...

AstraZeneca has also filed an oral SERD, camizestrant, targeting use of the drug in patients with advanced HR-positive breast ...

If the rest of 2026 continues in this vein, we may look back on January and February as the moment the sector recognised that ...